Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
VYXEOS vs AFINITOR DISPERZ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Daunorubicin and cytarabine are both antineoplastic agents. Daunorubicin intercalates with DNA, inhibits topoisomerase II, and generates free radicals leading to DNA damage and cell death. Cytarabine is a nucleoside analog that inhibits DNA polymerase by competing with cytidine triphosphate, incorporating into DNA and RNA, and causing chain termination.
Everolimus is an m TOR inhibitor that binds to FKBP-12, forming a complex that inhibits the m TOR serine-threonine kinase, thereby blocking cell cycle progression, angiogenesis, and cell growth.
FDA: Treatment of newly diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients aged 1 year and older.
Advanced hormone receptor-positive, HER2-negative breast cancer (postmenopausal women, in combination with exemestane),Advanced neuroendocrine tumors of pancreatic origin (unresectable, locally advanced, or metastatic),Advanced neuroendocrine tumors of gastrointestinal or lung origin (unresectable, locally advanced, or metastatic),Renal angiomyolipoma and tuberous sclerosis complex (TSC) not requiring immediate surgery,Subependymal giant cell astrocytoma (SEGA) associated with TSC,Renal cell carcinoma (advanced, after failure of sunitinib or sorafenib),Prevention of organ rejection in renal and cardiac transplant recipients (off-label: liver transplant)
Each unit contains 44 mg daunorubicin and 100 mg cytarabine. Adults: 1 unit/m² IV over 90 minutes on days 1, 3, and 5 for induction; up to 2 cycles. For consolidation: 1 unit/m² IV over 90 minutes on days 1 and 3; up to 2 cycles.
10 mg orally once daily for advanced hormone receptor-positive, HER2-negative breast cancer; 10 mg orally once daily for advanced pancreatic neuroendocrine tumors; 10 mg orally once daily for advanced renal cell carcinoma; 7.5 mg orally once daily for subependymal giant cell astrocytoma (SEGA); 5 mg orally once daily for tuberous sclerosis complex (TSC)-associated renal angiomyolipoma.
Daunorubicin: terminal half-life approximately 56 h; cytarabine: terminal half-life approximately 31 h. The prolonged half-lives reflect sustained release from liposomes, allowing continuous exposure.
Terminal half-life is approximately 30 hours (range 28-35 hours) in patients with advanced solid tumors, supporting once-daily dosing.
Daunorubicin is metabolized via aldo-keto reductases to daunorubicinol, which is active. Cytarabine is primarily metabolized by cytidine deaminase to inactive uracil arabinoside (ara-U).
Everolimus is metabolized primarily by CYP3A4 and is a substrate of P-glycoprotein (P-gp). It is also a moderate inhibitor of CYP3A4 and P-gp.
Primarily hepatobiliary excretion; 70-80% of dose recovered in feces as metabolites, less than 10% in urine as unchanged liposomal daunorubicin and cytarabine.
Primarily fecal (80%) with 22% as unchanged drug; renal excretion <5%.
Daunorubicin: approximately 60-70% bound to albumin and tissue proteins; cytarabine: approximately 15% bound to albumin.
Approximately 74% bound to plasma proteins (mainly albumin).
Daunorubicin: Vd approximately 0.5-1 L/kg, indicating extensive tissue distribution; cytarabine: Vd approximately 0.3-0.5 L/kg, distributed mainly in total body water.
Mean apparent volume of distribution is 47 L (approximately 0.6 L/kg), indicating extensive tissue distribution.
Not applicable (IV only); oral bioavailability not established for liposomal formulation.
Absolute bioavailability of the tablet formulation is approximately 16% after a high-fat meal; dispersible tablet bioavailability is comparable when taken with food.
Contraindicated in severe renal impairment (Cr Cl < 30 m L/min). For Cr Cl 30-60 m L/min: reduce dose by 25%. Monitor renal function.
For Cr Cl 30-50 m L/min: no adjustment required. For Cr Cl <30 m L/min: contraindicated or not recommended due to lack of data. No specific GFR-based dose reduction recommended.
Contraindicated in severe hepatic impairment (Child-Pugh C). For Child-Pugh B: reduce dose by 50%. For Child-Pugh A: no adjustment needed.
Child-Pugh A: reduce dose to 7.5 mg daily. Child-Pugh B: reduce dose to 5 mg daily. Child-Pugh C: contraindicated.
Safety and efficacy not established. No standard pediatric dosing. Use only in clinical trials.
For SEGA in TSC: weight-based dosing targeting AUC similar to adult 10 mg/day. Initial dose 2.5 mg/m² once daily, titrate to trough concentration 5-15 ng/m L. For TSC-associated renal angiomyolipoma: not established in pediatric patients.
No specific dose adjustment based on age alone. Monitor renal and hepatic function; consider dose reduction in frail elderly patients due to increased toxicity risk.
No specific dose adjustment required based on age alone; monitor renal function and dose adjust per renal/hepatic status. Elderly patients may have increased risk of adverse effects such as stomatitis, infections, and metabolic disturbances.
WARNING: DAUNORUBICIN IS A CARDIOTOXIC AGENT. DAUNORUBICIN CAN CAUSE MYELOSUPPRESSION AND SEVERE BLEEDING. VYXEOS IS A LIPOSOMAL FORMULATION; DO NOT SUBSTITUTE FOR OTHER DAUNORUBICIN OR CYTARABINE PRODUCTS.
There is no FDA black box warning for Afinitor Disperz. However, serious infections, including opportunistic infections, may occur.
Cardiotoxicity: Left ventricular dysfunction, especially with cumulative doses; monitor cardiac function.,Myelosuppression: Severe, can lead to fatal infections or bleeding.,Hemorrhage: Fatal hemorrhages reported.,Tumor lysis syndrome: Risk due to rapid lysis.,Hepatotoxicity: Elevations in bilirubin and transaminases.,Embryo-fetal toxicity: Can cause fetal harm; advise effective contraception.
Non-infectious pneumonitis (including interstitial lung disease) has been reported; monitor for symptoms and consider interruption or discontinuation.,Increased risk of infections, including opportunistic infections (e.g., Pneumocystis jirovecii, TB); monitor and treat promptly.,Increased serum creatinine and proteinuria may occur; monitor renal function.,Angioedema, including life-threatening cases, can occur, especially in patients taking ACE inhibitors.,Stomatitis and mouth ulcers are common; manage with topical treatments and dose modification.,Impaired wound healing; use with caution perioperatively.,Increased risk of bleeding, especially in patients with renal angiomyolipoma and TSC.,Fetal harm can occur; advise effective contraception during treatment.
Hypersensitivity to daunorubicin, cytarabine, or any component of the formulation.,History of serious hypersensitivity reactions to any conventional daunorubicin or cytarabine product.
Hypersensitivity to everolimus, sirolimus, or any component of the formulation,Severe hepatic impairment (Child-Pugh class C) (relative contraindication; use with caution in moderate impairment)
No specific food interactions reported. Avoid grapefruit and grapefruit juice due to potential CYP3A4 interaction with other components, although data are limited. Maintain adequate hydration to prevent tumor lysis syndrome.
Avoid grapefruit, grapefruit juice, and Seville oranges due to CYP3A4 inhibition. Avoid high-fat meals, as they reduce absorption; take on empty stomach or with light fat-free meal. St. John's wort reduces everolimus levels and should be avoided.
VYXEOS (daunorubicin and cytarabine liposome) is contraindicated in pregnancy. It is embryotoxic and fetotoxic in animals. First trimester: high risk of major malformations (neural tube, cardiac). Second/third trimester: risk of fetal growth restriction, preterm birth, and neonatal myelosuppression. Use effective contraception.
Pregnancy Category D. Animal studies show embryotoxicity and fetotoxicity at subtherapeutic doses. First trimester: risk of major malformations. Second/third trimester: risk of fetal growth restriction, oligohydramnios, and spontaneous abortion.
Not recommended. It is unknown if excreted into human milk. M/P ratio not available. Advise to discontinue breastfeeding during treatment and for at least 1 month after last dose due to potential for serious adverse reactions in breastfed infants.
No data on excretion in human milk; M/P ratio unknown. Due to potential serious adverse reactions in nursing infants (e.g., immunosuppression), breastfeeding is contraindicated during treatment and for 2 weeks after last dose.
No established dosing guidelines in pregnancy. Avoid use; if therapy is necessary, dose adjustments based on pharmacokinetic changes are not defined. Use only if potential benefit justifies risk to fetus.
No specific dose adjustments established for pregnancy. Pharmacokinetic changes (increased volume of distribution, altered metabolism) may reduce exposure; however, due to teratogenicity, use is not recommended unless benefit outweighs risk. Dose adjustments based on therapeutic drug monitoring are not validated.
VYXEOS is a liposomal encapsulation of daunorubicin and cytarabine in a fixed 1:5 molar ratio. It is indicated for adults with newly diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC). Do not substitute with other daunorubicin/cytarabine products due to different pharmacokinetics. Monitor for cardiotoxicity (echocardiogram prior to each cycle), myelosuppression, and hepatotoxicity. Premedicate for infusion reactions. Administer as a 90-minute IV infusion on days 1, 3, and 5; no dose adjustment for mild-moderate renal or hepatic impairment but avoid in severe impairment.
AFINITOR DISPERZ (everolimus) is an m TOR inhibitor; tablets for oral suspension are not interchangeable with regular tablets due to different pharmacokinetics. Monitor for non-infectious pneumonitis, rash, stomatitis, metabolic effects (hyperglycemia, hyperlipidemia), and renal impairment. Dose adjustments required for hepatic impairment and concurrent strong CYP3A4/P-gp inhibitors or inducers. Avoid live vaccines during treatment.
VYXEOS is a combination chemotherapy used for certain types of acute myeloid leukemia.,It is given as an intravenous infusion over 90 minutes on days 1, 3, and 5 of each treatment cycle.,Common side effects include fever, infection, nausea, vomiting, diarrhea, constipation, mouth sores, fatigue, and bleeding or bruising.,You will have regular blood tests to monitor blood counts, heart function, and liver function.,Report any signs of infection (fever, chills), bleeding (unusual bruising, black stools), shortness of breath, or chest pain immediately.,Avoid pregnancy and breastfeeding while on this medication.,Do not take any other medications, including over-the-counter drugs or supplements, without consulting your doctor.
Take exactly as prescribed; do not crush or chew tablets for oral suspension.,Mix dose with water only, do not mix with juice or other liquids.,Avoid grapefruit, grapefruit juice, and Seville oranges during treatment.,Report any new or worsening shortness of breath, cough, or chest pain immediately.,Use effective non-hormonal contraception during and for 8 weeks after last dose.,Avoid live vaccines and close contact with recently vaccinated individuals.,Monitor for mouth sores; use alcohol-free mouthwash and soft toothbrush.,Do not take St. John's wort or strong CYP3A4/P-gp inhibitors/inducers without consulting doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about VYXEOS vs AFINITOR DISPERZ, answered by our medical review team.
VYXEOS is a Liposomal Antineoplastic Combination that works by Daunorubicin and cytarabine are both antineoplastic agents. Daunorubicin intercalates with DNA, inhibits topoisomerase II, and generates free radicals leading to DNA damage and cell death. Cytarabine is a nucleoside analog that inhibits DNA polymerase by competing with cytidine triphosphate, incorporating into DNA and RNA, and causing chain termination.. AFINITOR DISPERZ is a mTOR Inhibitor Antineoplastic that works by Everolimus is an m TOR inhibitor that binds to FKBP-12, forming a complex that inhibits the m TOR serine-threonine kinase, thereby blocking cell cycle progression, angiogenesis, and cell growth.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between VYXEOS and AFINITOR DISPERZ depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of VYXEOS is: Each unit contains 44 mg daunorubicin and 100 mg cytarabine. Adults: 1 unit/m² IV over 90 minutes on days 1, 3, and 5 for induction; up to 2 cycles. For consolidation: 1 unit/m² IV over 90 minutes on days 1 and 3; up to 2 cycles.. The standard adult dose of AFINITOR DISPERZ is: 10 mg orally once daily for advanced hormone receptor-positive, HER2-negative breast cancer; 10 mg orally once daily for advanced pancreatic neuroendocrine tumors; 10 mg orally once daily for advanced renal cell carcinoma; 7.5 mg orally once daily for subependymal giant cell astrocytoma (SEGA); 5 mg orally once daily for tuberous sclerosis complex (TSC)-associated renal angiomyolipoma.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between VYXEOS and AFINITOR DISPERZ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. VYXEOS is classified as Category C. VYXEOS (daunorubicin and cytarabine liposome) is contraindicated in pregnancy. It is embryotoxic and fetotoxic in animals. First trimester: high risk of major malformations (neural. AFINITOR DISPERZ is classified as Category C. Pregnancy Category D. Animal studies show embryotoxicity and fetotoxicity at subtherapeutic doses. First trimester: risk of major malformations. Second/third trimester: risk of fet. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.